LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist.

    Serwer, Philip

    Antibiotics (Basel, Switzerland)

    2020  Volume 9, Issue 5

    Abstract: ... responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose ... pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate ... of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine ...

    Abstract Recently, the research community has had a real-world look at reasons for improving vaccine responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose two alternative options and compare the primary alternative option with current practice. The basis of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine on 2-4 week notice. The primary option is the following. (1) Start with a platform based on live viruses that infect bacteria, but not humans (bacteriophages, or phages). (2) Isolate phages (to be called pathogen homologs) that resemble and provide antigenic context for membrane-covered, pathogenic RNA viruses; coronavirus-phage homologs will probably be found if the search is correctly done. (3) Upon isolating a viral pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate with the evolved phage homolog by generating a local, non-hazardous infection with the phage host and then curing the infection by propagating the phage in the artificially infecting bacterial host. I discuss how this alternative option has the potential to provide what is needed after appropriate platforms are built.
    Keywords covid19
    Language English
    Publishing date 2020-05-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics9050255
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Optimizing anti-viral vaccine responses: Input from a non-specialist

    Serwer, Philip

    Antibiotics

    Abstract: ... responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose ... pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate ... of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine ...

    Abstract Recently, the research community has had a real-world look at reasons for improving vaccine responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose two alternative options and compare the primary alternative option with current practice. The basis of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine on 2–4 week notice. The primary option is the following. (1) Start with a platform based on live viruses that infect bacteria, but not humans (bacteriophages, or phages). (2) Isolate phages (to be called pathogen homologs) that resemble and provide antigenic context for membrane-covered, pathogenic RNA viruses; coronavirus-phage homologs will probably be found if the search is correctly done. (3) Upon isolating a viral pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate with the evolved phage homolog by generating a local, non-hazardous infection with the phage host and then curing the infection by propagating the phage in the artificially infecting bacterial host. I discuss how this alternative option has the potential to provide what is needed after appropriate platforms are built.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #665441
    Database COVID19

    Kategorien

To top